Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving [(177)Lu]Lu-PSMA-617 radioligand therapy

Prostate-specific membrane antigen (PSMA) is a promising target for the diagnosis of and therapy for metastatic castration-resistant prostate cancer (mCRPC). The aim of this study was to measure overall-survival (OS) in mCRPC patients who received either abiraterone or enzalutamide prior to PSMA the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Ahmadzadehfar, Hojjat, Schlolaut, Stephan, Fimmers, Rolf, Yordanova, Anna, Hirzebruch, Stefan, Schlenkhoff, Carl, Gaertner, Florian C., Awang, Zool Hilmi, Hauser, Stefan, Essler, Markus
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732715/
https://ncbi.nlm.nih.gov/pubmed/29262549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21600
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados